Effect of methotrexate and doxorubicin cumulative doses on superoxide dismutase levels in childhood acute lymphoblastic leukemia
Abstract: Background Acute lymphoblastic
leukemia (ALL) is the most common malignancy in children. Chemotherapeutic
drugs for ALL such as methotrexate (Mtx) and doxorubicin produce reactive
oxygen species (ROS), a type of free radical. The ROS can reduce levels of
antioxidants in the body, including superoxide dismutase (SOD). Decreased SOD
levels can cause DNA, lipid, and protein damage, which in turn may lead to
adverse effects and treatment failure. Objective To determine the effect of Mtx
and doxorubicin cumulative doses on SOD levels in children with ALL. Methods We
conducted a retrospective cohort study in children with ALL who underwent
chemotherapy in Dr. Sardjito Hospital in October 2011 who had completed the
induction phase. Risk factors for decreased SOD levels were analyzed by Cox
regression and hazard ratio, with a significant level of P <0.05.
Results2ISDWLHQWVHQUROOHG0W[PJP2 significantly decreased SOD levels (HR 9.959;
95%CI 2.819 to 35.183; 3 +RZHYHUGR[RUXELFLQPJP2 did not significantly decrease
SOD levels (HR 0.59 95%CI 0.194 to 1.765; P=0.34). Conclusion Methotrexate is
associated with decreased SOD levels in children with ALL. However, doxorubicin
is not associated with decreased SOD levels in the same patient population.
Author: Khalida Fetriyani
Ningsih, Sri Mulatsih, Sasmito Nugroho
Journal Code: jpkedokterangg150260
